Assessing developability early in the discovery process for novel biologics
Beyond potency, a good developability profile is a key attribute of a biological drug.
Selecting and screening for such attributes early in the drug development process can save …
Selecting and screening for such attributes early in the drug development process can save …
[HTML][HTML] Predicting bioavailability of monoclonal antibodies after subcutaneous administration: open innovation challenge
M Sánchez-Félix, M Burke, HH Chen… - Advanced drug delivery …, 2020 - Elsevier
Despite the increasing trend towards subcutaneous delivery of monoclonal antibodies,
factors influencing the subcutaneous bioavailability of these molecules remain poorly …
factors influencing the subcutaneous bioavailability of these molecules remain poorly …
Optimization of therapeutic antibodies for reduced self-association and non-specific binding via interpretable machine learning
Antibody development, delivery, and efficacy are influenced by antibody-antigen affinity
interactions, off-target interactions that reduce antibody bioavailability and …
interactions, off-target interactions that reduce antibody bioavailability and …
A single molecular descriptor to predict solution behavior of therapeutic antibodies
JS Kingsbury, A Saini, SM Auclair, L Fu, MM Lantz… - Science …, 2020 - science.org
Despite the therapeutic success of monoclonal antibodies (mAbs), early identification of
developable mAb drug candidates with optimal manufacturability, stability, and delivery …
developable mAb drug candidates with optimal manufacturability, stability, and delivery …
Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches
With the growing significance of antibodies as a therapeutic class, identifying developability
risks early during development is of paramount importance. Several high-throughput in vitro …
risks early during development is of paramount importance. Several high-throughput in vitro …
The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement
M Brinkhaus, E Pannecoucke, EJ van der Kooi… - Nature …, 2022 - nature.com
Binding to the neonatal Fc receptor (FcRn) extends serum half-life of IgG, and antagonizing
this interaction is a promising therapeutic approach in IgG-mediated autoimmune diseases …
this interaction is a promising therapeutic approach in IgG-mediated autoimmune diseases …
Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier
J Tien, D Leonoudakis, R Petrova, V Trinh, T Taura… - MAbs, 2023 - Taylor & Francis
The blood-brain barrier (BBB) largely excludes antibodies from entering the central nervous
system, thus limiting the potential of therapeutic antibodies to treat conditions such as …
system, thus limiting the potential of therapeutic antibodies to treat conditions such as …
Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods
There is intense and widespread interest in developing monoclonal antibodies as
therapeutic agents to treat diverse human disorders. During early-stage antibody discovery …
therapeutic agents to treat diverse human disorders. During early-stage antibody discovery …
Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies
ABSTRACT A growing body of evidence supports the important role of molecular charge on
antibody pharmacokinetics (PK), yet a quantitative description of the effect of charge on …
antibody pharmacokinetics (PK), yet a quantitative description of the effect of charge on …
In translation: FcRn across the therapeutic spectrum
T Qi, Y Cao - International Journal of Molecular Sciences, 2021 - mdpi.com
As an essential modulator of IgG disposition, the neonatal Fc receptor (FcRn) governs the
pharmacokinetics and functions many therapeutic modalities. In this review, we thoroughly …
pharmacokinetics and functions many therapeutic modalities. In this review, we thoroughly …